Form 4: Immunocore R&D Head Sells Shares Post-RSU Vesting

Immunocore's Head of R&D, David M. Berman, sold a portion of his vested ordinary shares to cover tax liabilities following the exercise of restricted share units.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, acquired 11,824 Ordinary Shares on February 17, 2026, through the vesting of Restricted Share Units (RSUs).
• On February 18, 2026, Mr. Berman sold 5,965 Ordinary Shares at a weighted average price of $32.35 per share.
• The sale was a "sell-to-cover" transaction, executed to satisfy income tax liabilities incurred upon the RSU vesting.
• Following these transactions, Mr. Berman beneficially owns 5,859 Ordinary Shares directly and 35,473 Restricted Share Units directly.
• The RSUs were part of a grant of 47,297 RSUs on February 17, 2025, vesting in four equal annual installments starting February 17, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves an insider sale, it's a routine 'sell-to-cover' for tax purposes following RSU vesting, indicating continued executive compensation and retention rather than a change in sentiment.

Positives

• The vesting of 11,824 Restricted Share Units indicates continued executive compensation and retention of a key R&D leader.
• The transaction demonstrates the company's equity compensation plan is functioning as intended, aligning management incentives with shareholder value.

Negatives

• An insider sale, even for tax purposes, reduces the direct shareholding of a key executive, though the remaining RSU holdings are substantial.

Future Outlook

The remaining 35,473 Restricted Share Units held by David M. Berman are scheduled to vest in three additional equal annual installments, subject to his continuous service through each vesting date.

Management Comments

• The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine practice for executives in the biotechnology and broader corporate sectors when equity awards, such as Restricted Share Units, vest. This mechanism allows executives to meet tax obligations arising from the vesting event without needing to use personal funds, and it is generally viewed as a standard part of executive compensation plans.

Comparison to Industry Standards

• This transaction aligns with typical executive compensation practices across the pharmaceutical and biotechnology industries, where equity awards like RSUs are a significant component of remuneration.
• Companies such as Moderna (MRNA), BioNTech (BNTX), and Regeneron Pharmaceuticals (REGN) frequently utilize similar equity compensation structures, leading to comparable 'sell-to-cover' transactions by their executives upon vesting events.
• The sale of shares to cover tax liabilities is a standard, predictable outcome of such compensation, rather than an indicator of a change in an executive's long-term view of the company.

Stakeholder Impact

• Shareholders: The sale represents a minor increase in the public float, but the underlying RSU vesting indicates continued executive alignment with company performance.
• Employees: The RSU vesting and subsequent tax-related sale are standard components of executive compensation, which can serve as a model for broader employee equity programs.

Next Steps

• Future vesting of the remaining 35,473 Restricted Share Units in three equal annual installments.

Key Dates

Recommendation

This Form 4 details a routine 'sell-to-cover' transaction by a key executive to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's long-term commitment. Therefore, a seasoned investor would likely maintain their current position, as this event does not provide new information warranting a change in investment strategy.

Keywords

Immunocore, IMCR, Form 4, insider transaction, Restricted Share Units, RSU vesting, executive compensation, David M. Berman, sell-to-cover, biotechnology